SYNkinase’s mission is to provide life-science researchers with access to the world’s most up-to-date library of kinase inhibitors, and other small molecule inhibitors of important therapeutic proteins, for drug-discovery research use. With guidance from our founders, that include kinase biology scientists and expert medicinal and synthetic chemists, we have created a library of potent, pure and research-relevant inhibitors directed against specific protein serine/threonine kinases (PS/TKs), protein tyrosine kinases (PTK & RTK), as well as lipid kinases.
There are more than 150 Kinase targeted drugs in clinical trials or development at present. Twenty four small molecule inhibitors have been FDA-approved including mTOR, B-Raf, MEK, EGFR, JAK, VEGFR and PI3K inhibitors. SYNkinase has many of these compounds available for sale as well as a large range of inhibitors described in the literature such as GPCR and epigenetic inhibitors.
Importantly, as we are a primary source manufacturer we can maintain a fastidious focus on quality, as well as being first in the market with the most important and topical compounds. SYNkinase offers its inhibitor collections in several formats, including pre-formatted and custom arrays.
Kinase Inhibitors, Small Molecule Inhibitors, Custom Synthesis, Medicinal Chemistry